Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors
- Author(s)
- Rangamuwa, K; Leong, T; Weeden, C; Asselin-Labat, ML; Bozinovski, S; Christie, M; John, T; Antippa, P; Irving, L; Steinfort, D;
- Details
- Publication Year 2021-06,Volume 10,Issue #6,Page 2842-2857
- Journal Title
- Translational Lung Cancer Research
- Abstract
- Lung cancer is the leading cause of cancer death worldwide, with approximately 1.6 million cancer related deaths each year. Prognosis is best in patients with early stage disease, though even then five-year survival is only 55% in some groups. Median survival for advanced non-small cell lung cancer (NSCLC) is 8-12 months with conventional treatment. Immune checkpoint inhibitor (ICI) therapy has revolutionised the treatment of NSCLC with significant long-term improvements in survival demonstrated in some patients with advanced NSCLC. However, only a small proportion of patients respond to ICI, suggesting the need for further techniques to harness the potential of ICI therapy. Thermal ablation utilizes the extremes of temperature to cause tumour destruction. Commonly used modalities are radiofrequency ablation (RFA), cryoablation and microwave ablation (MWA). At present thermal ablation is reserved for curative-intent therapy in patients with localized NSCLC who are unable to undergo surgical resection or stereotactic ablative body radiotherapy (SABR). Limited evidence suggests that thermal ablative modalities can upregulate an anticancer immune response in NSCLC. It is postulated that thermal ablation can increase tumour antigen release, which would initiate and upregulated steps in the cancer immunity cycle required to elicit an anticancer immune response. This article will review the current thermal ablative techniques and their ability to modulate an anti-cancer immune response with a view of using thermal ablation in conjunction with ICI therapy.
- Publisher
- AME Publishing Company
- Keywords
- Non-small cell lung cancer (NSCLC); cancer immunity; immunotherapy; thermal ablation
- Research Division(s)
- Personalised Oncology
- PubMed ID
- 34295682
- Publisher's Version
- https://doi.org/10.21037/tlcr-20-1075
- Open Access at Publisher's Site
https://doi.org/10.21037/tlcr-20-1075- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2021-08-16 10:40:55
Last Modified: 2021-08-16 11:24:36